XTAE
ICHO
Market cap355mUSD
Oct 30, Last price
115.30ILS
1D
-0.69%
1Q
17.65%
Jan 2017
-46.32%
IPO
-97.17%
Name
DNA Group TR Ltd
Chart & performance
P/E
50.51
P/S
3,646.92
EPS
0.02
Vol. 1Y
38.68%
Shs. 5Y
37.59%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
306k
0.00%
Net income
22m
P
CFO
2m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Israel Canada Hotels Ltd, operating through its various subsidiaries, is globally involved in the creation, production, and distribution of patented ultrasound technology. These advanced systems are instrumental in assessing bone strength and density, alongside tracking calcium loss, especially for diagnosing osteoporosis in both adults and children. Beyond its medical device activities, the company also engages in the development of oral pharmaceuticals. Incorporated in 2004 and based in Tel Aviv, Israel, the entity, which was previously known as Dna Group (T.R.) Ltd, is set to formally adopt the name Israel Canada Hotels Ltd in November 2025.
Key people
Chairman of the Board · since 2013
Chief Executive Officer, Director · since 2010
Vice President - Finance · since 2015
Internal Auditor · since 2010
Ronen Midbari
External Director · since 2019
External Director · since 2013
Independent Director · since 2014
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||